We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Xceleron and Sanofi-Aventis Sign Deal to Address Challenges in Exploratory Clinical Development

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Xceleron has announced that, following signature of a Master Services Agreement with Sanofi-Aventis Deutschland GmbH, a number of studies are underway to assess the human metabolism of novel compounds in early clinical development. This work utilises Xceleron’s ultra-sensitive Accelerator Mass Spectrometry (AMS) technology platform.

This latest deal adds to Xceleron’s growing client list of major organisations – including 15 of the world’s top 20 pharma companies.

Xceleron’s foundation in 1997 was supported by GSK, Novartis, Pfizer and Janssen (now Johnson & Johnson). Notably after many years of working with Xceleron to explore the potential of AMS, GSK now have 2 AMS machines of their own - focused specifically on similar kinds of metabolite profiling studies to those now being undertaken by Sanofi-Aventis.